Abstract
| Lingua originale | English |
|---|---|
| pagine (da-a) | 875-885 |
| Numero di pagine | 11 |
| Rivista | EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY |
| Volume | 8 |
| Stato di pubblicazione | Published - 2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
- Medicine(all)
- Gastroenterology
Cita questo
The role of targeted therapy for gastrointestinal tumors. / Fiorentino, Eugenio; Russo, Antonio; Bronte, Giuseppe; Sortino, Giovanni; Passiglia, Francesco; Papadimitriou, Konstantinos; Rolfo, Christian; Marogy, Ghada; Peeters, Marc; Papadimitriou, Konstantinos; Passiglia, Francesco.
In: EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, Vol. 8, 2014, pag. 875-885.Risultato della ricerca: Article
}
TY - JOUR
T1 - The role of targeted therapy for gastrointestinal tumors
AU - Fiorentino, Eugenio
AU - Russo, Antonio
AU - Bronte, Giuseppe
AU - Sortino, Giovanni
AU - Passiglia, Francesco
AU - Papadimitriou, Konstantinos
AU - Rolfo, Christian
AU - Marogy, Ghada
AU - Peeters, Marc
AU - Papadimitriou, Konstantinos
AU - Passiglia, Francesco
PY - 2014
Y1 - 2014
N2 - Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
AB - Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
UR - http://hdl.handle.net/10447/109880
UR - http://www.future-drugs.com/page/journal/egh/teaser.jsp
M3 - Article
VL - 8
SP - 875
EP - 885
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
SN - 1747-4124
ER -